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EFFECT OF SLC22A1 GENE POLYMORPHISMS ON METFORMINRESPONSE IN
LEBANESE TYPE 2 DIABETES MELLITUS PATIENTS
Abstract
Metformin is one of the most widely prescribed oral ant diabetic drugs, it is generally used for treating type
2 diabetes mellitus patients. The organic caution transporter 1(OCT1), encoded by the SLC22A1 gene is
responsible for the uptake of metformin in the hepatocytes. Polymorphisms in SLC22A1 gene contribute to
variable responses to metformin leading to inter-individual variations in its clinical efficacy. We evaluated
the impact of SLC22A1 rs622342 gene polymorphisms on the efficacy of metformin in Lebanese type
2 diabetes mellitus patients. A total of 63 patients who were on metformin monotherapy were followed
up for 6 months. Single nucleotide polymorphisms were determined using Simple Probe® real-time PCR
assay. The percentage reduction of fasting plasma glucose after 3 months were 31 % in patients having
AA genotype slightly higher than in patients having AC genotype 30.3 % (P=0.676) but much higher than
in patients carrying two copies of ‘‘C’’ allele 19.7% (P < 0.001).The percentage reduction of HbA1c after 3
months were 11.16 % in patients having AA genotype higher than in patients having AC genotype 8.58 %
(P=0.04) and much higher than in patients carrying two copies of ‘‘C’’ allele 5.65% (P=0.011).Similar results
are shown after 6 months. Although preliminary, these data suggest that metformin response in individuals
with diabetes mellitus patients may vary according to rs622342 in SLC22A1.
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ABSTRACT: Metformin is one of the most widely prescribed oral ant diabetic drugs, it is
generally used for treating type 2 diabetes mellitus patients. The organic caution transporter
1(OCT1), encoded by the SLC22A1 gene is responsible for the uptake of metformin in the
hepatocytes. Polymorphisms in SLC22A1 gene contribute to variable responses to metformin
leading to inter-individual variations in its clinical efficacy. We evaluated the impact of
SLC22A1 rs622342 gene polymorphisms on the efficacy of metformin in Lebanese type 2
diabetes mellitus patients. A total of 63 patients who were on metformin monotherapy were
followed up for 6 months. Single nucleotide polymorphisms were determined using Simple
Probe® real-time PCR assay. The percentage reduction of fasting plasma glucose after 3
months were 31 % in patients having AA genotype slightly higher than in patients having AC
genotype 30.3 % (P=0.676) but much higher than in patients carrying two copies of ‘‘C’’
allele 19.7% (P<0.001).The percentage reduction of HbA1c after 3 months were 11.16 % in
patients having AA genotype higher than in patients having AC genotype 8.58 % (P=0.04)
and much higher than in patients carrying two copies of ‘‘C’’ allele 5.65%
(P=0.011).Similar results are shown after 6 months. Although preliminary, these data
suggest that metformin response in individuals with diabetes mellitus patients may vary
according to rs622342 in SLC22A1.

KEYWORDS: Type 2 diabetes mellitus, metformin, organic cation transporter 1, rs622342 gene polymorphisms.
1. INTRODUCTION
Type 2 diabetes mellitus T2DM has become epidemic. The Middle East North Africa region has
one of the highest rates of diabetes, both in prevalence and in rate of increase (Nasrallah, et al., 2017). Parallel
with lifestyle changes, the pharmacological treatment in T2DM is usually initiated with oral antidiabetic drug
monotherapy.
Metformin which belongs to the class of biguanides is the most commonly used diabetes therapy, with
over 100 million patients prescribed this drug per year globally (Rena et al.,2012), it is a drug with low cost
and long known experience with well-established safety profile (Somasundaram,2016).
Metformin is a complex drug with multiple sites of action and multiple molecular mechanisms.
Physiologically, metformin acts directly or indirectly on the liver to lower glucose production, and acts on the
gut to increase glucose utilization. At the molecular level, metformin inhibits the mitochondrial respiratory
chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity (via effects on fat metabolism)
and lowering cAMP, thus reducing the expression of gluconeogenic enzymes. Metformin also has AMPKindependent effects on the live that may include inhibition of fructose-1,6-bisphosphatase by AMP (Rena et
al.,2017).
Chemically, Metformin is a hydrophilic base which exists at physiological pH as the cationic species.
Consequently, its passive diffusion through cell membranes should be very limited. The mean fractional oral
bioavailability of metformin is 55 – 16%. It is absorbed predominately from the small intestine. Metformin is
excreted unchanged in urine; metabolites of the drug have not been identified. The elimination half-life of
metformin is approximately 5 hours (Rena et al.,2012).
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The organic cation transporter, OCT1, an influx transporter encoded by SLC22A1located at chromosome
6q25.3, interacts with a variety of structurally diverse compounds and drugs including metformin (Shu et
al.,2008). Given the fact that OCT1 is predominantly expressed on the basolateral side of hepatocytes, OCT1
is believed to be the most important transporter for the pharmacological action of metformin (Sam et al.,2017).
Hepatic uptake of metformin is dramatically reduced in Oct1−/− mice compared to Oct1+/+ mice after
metformin administration (Shu et al.,2008). Genetic variants of SLC22A1 have been shown to modulate the
pharmacokinetics of metformin after oral administration and reduce the therapeutic response, presumably by
decreasing the hepatic uptake of the drug (Shu et al.,2007). SLC22A1is highly polymorphic in ethnically
diverse populations and polymorphisms in SLC22A1 have been shown to cause differences in transporter
function. Therefore, SLC22A1 play a significant role in causing inter-patient and inter-ethnic differences in
the therapeutic efficacy and disposition of metformin (Singh et al.,2016).
In this study we evaluated the significance of the genetic polymorphism (rs622342) of SLC22A1 gene
with regard to the efficacy of metformin patients with type 2 diabetes in the Lebanese population.
2. MATERIAL AND METHODS
2.1 Study Subjects
The study was carried out in 63 unrelated Lebanese T2DM patients of either sex (26 women and 37
men; range 44–66 years). The subjects were recruited between September 2013 and May 2015.
Diagnosis of diabetes was made by applying the World Health Organization criteria.
Patients with a history of liver or renal disease, pregnancy and lactation, congestive cardiac failure
and myocardial infarction were excluded. A detailed history was taken from all participants and all
subjects gave informed consent before participating. All selected patients were started on metformin
monotherapy 850 mg and advised lifestyle as well as dietary modifications.
2.2 Clinical Laboratory Tests
Body mass index (BMI) were documented at the first visit. Average fasting plasma blood glucose,
glycated hemoglobin (HbA1c) and fasting lipid profile (Total cholesterol TC, Triglycerides TG, high
density lipoprotein HDL and low density lipoprotein LDL) were recorded at baseline and after 3 months
and 6 months of treatment with metformin.
2.3 DNA Sampling and Genotyping
Whole blood samples were collected in tubes containing EDTA.DNA extraction was performed using
GenElute Blood Genomic DNA Kit (Sigma-Aldrich) according to the manufacturer’s manual.
The DNA concentration and quality were evaluated by Geneva Nano drop (Jenway). The prepared
DNA was stored at -20⁰C until being used.
SimpleProbe® real-time PCR assay for SLC22A1 rs622342 was performed using lightSNiP Kit
human rs622342 (TIB MOLBIOL GmbH, Berlin, Germany) in 20 μL PCR mixture final volume
composed of 2 μL LightCycler® Fast Start DNA Master HybProbe® (Roche Diagnostics, USA), 1 μL
Primer and Probe (TIB MOLBIOL GmbH,Berlin, Germany), and 5 μL extracted DNA. Amplification
was performed in the following conditions: activation step at 95°C for 10 minutes and 45 cycles of three
thermal amplification steps: 95°C for 10 seconds,60°C for 10 seconds, and 72°C for 15 seconds. The
genotypes were identified by running melting curves.
Amplification was performed on real-time thermal cycler CFX96™ (Bio-Rad), data acquisition and
melting curve analysis were performed using CFX Manager™ Software.
2.4 Statistics
SPSS version 22.0 was used for data analysis. Group differences for continuous variables are assessed
by ANOVA and categorical variables by χ2 test. P value ˂0.05 was considered significant.
3. RESULTS
3.1 Genotyping
SimpleProbe® real-time PCR assay was used to detect SLC22 gene (rs622342) polymorphism in
the study group. SimpleProbe® real-time PCR is able to detect wild type, heterozygous and mutant
genotypes based on their melting point. Figure 1 shows schematic results of genotyping by real-time PCR.
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Fig .1 Schematic Representation of Genotyping Pattern by SimpleProbe® Real-Time PCR
Reference: Photographed by the author March 2018
3.2 Allele and Genotype Frequency Distribution
A total of 63 T2DM Lebanese patients were enrolled to explore the allele frequencies and genotype
frequencies of SLC22 gene (rs622342) polymorphism.
The allele and genotype frequency distribution of SLC22 gene (rs622342) polymorphisms in T2DM
patients are summarized in Table 1. The observed genotype frequency of the polymorphism did not show
significant deviation from expected frequency according to Hardy–Weinberg equilibrium.
Table 1: Genotype and allele frequency distribution of SLC22A1 (rs622342) gene polymorphism

Genotype
Allele

AA
AC
CC
A
C
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Male

Female

Total

25
9
3
59
15

20
5
1
45
7

45 (71.4%)
14 (33%)
4 (6.3%)
104 (83.5%)
22 (17.5%)
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3.3 Influence of SLC22A1 (rs622342) Polymorphisms on Therapeutic Efficacy of Metformin in T2DM
Patients.
Average fasting plasma blood glucose, glycated hemoglobin (HbA1c) and fasting lipid profile were
recorded at baseline and after 3 months and 6 months of metformin monotherapy treatment.
As shown in table 2 there was a significant difference between groups in the percentage of decrease
in fasting blood glucose after 3 months (P ˂ 0.001) and after 6 months (P˂ 0.001); the difference was also
significant in the percentage decrease of glycated hemoglobin after 3 months (P =0.021) and after 6
months (P=0.009).
No significant difference between groups was shown regarding the variation in the lipid profile tests
(TG, TC, HDL and LDL).
The percentage decrease of FPG after 3 months was 30.32 ± 5.85 in AC patients slightly less than the
decrease in wild type AA patients 30.99 ± 5.12 (P= 0.67, table 3), this decrease was significantly less in
CC patients 19.73 ± 2.97 (P ˂ 0.001, table 3). Similar results were shown after 6 months of treatment.
The percentage decrease of HbA1C after 3 months was 8.58 ± 4.09 in AC patients significantly less
than the decrease in wild type AA patients 11.16 ± 3.95 (P= 0.040, table 3), this decrease was even less
in CC patients 5.65 ± 4.59 (P = 0.011, table 3). Similar results were shown after 6 months of treatment.
Table 2: Comparisons of differential values (pre-administration minus post-administration) in patients with
different of SLC22A1 (rs622342) genotypes before and after metformin treatment for 3 and 6 months.
All values are expressed as mean ± SD
Genotype
Parameter
Baseline
After 3 months
3 months % change
After 6 months
6 months % change
Baseline
After 3 months
3 months % change
After 6 months
6 months % change
Baseline
After 3 months
3 months % change
After 6 months
6 months % change
Baseline
After 3 months
3 months % change
After 6 months
6 months % change
Baseline
After 3 months
3 months % change
After 6 months
6 months % change
Baseline
After 3 months
3 months % change
After 6 months
6 months % change

FPG

HbA1C

TG

TC

HDL

LDL

AA
162.82 ± 20.76
111.87 ± 12.73
30.99 ± 5.12
110.18 ± 11.71
31.94 ± 5.35
7.69 ± 0.53
6.82 ± 0.41
11.16 ± 3.95
6.77 ± 0.38
11.72 ± 3.79
173.04 ± 14.52
162.53 ± 13.43
5.98 ± 4.04
159.47 ± 13.39
7.68 ± 5.54
214.02 ± 16.04
207.09 ± 13.48
3.13 ± 2.94
201.04 ± 12.92
5.89 ± 4.34
42.51 ± 5.19
45.71 ± 4.66
-8.03 ± 7.42
46.80 ± 4.47
-10.84 ± 9.86
136.98 ± 19.52
128.91 ± 16.03
5.51 ± 5.50
120.22 ± 19.35
11.47 ± 12.38

AC
160.50 ± 23.41
111.00 ± 12.89
30.32 ± 5.85
110.79 ± 12.03
30.58 ± 5.95
7.67 ± 0.58
7.01 ± 0.55
8.58 ± 4.09
6.96 ± 0.45
9.14 ± 4.42
182.43 ± 17.54
173.64 ± 16.67
4.73 ± 3.87
170.71 ± 16.85
6.21 ± 6.31
222.36 ± 16.17
214.07 ± 16.63
3.68 ± 3.79
207.50 ± 16.59
6.56 ± 5.50
39.64 ± 6.10
42.50 ± 6.14
-7.70 ± 10.64
44.07 ± 5.95
-11.92 ± 11.73
141.36 ± 18.80
136.79 ± 20.00
2.66 ± 12.56
129.36 ± 19.57
7.74 ± 13.87

CC
159.00 ± 18.56
127.25 ± 10.78
19.73 ± 2.97
126.50 ± 12.76
20.28 ± 2.63
7.9 ± 0.29
7.45 ± 0.38
5.65 ± 4.59
7.40 ± 0.36
6.29 ± 4.16
187.25 ± 8.18
173.25 ± 7.93
7.45 ± 2.85
176.00 ± 15.85
6.07 ± 6.14
213.75 ± 3.59
208.50 ± 7.00
2.47 ± 2.02
202.50 ± 5.06
5.25 ± 2.27
42.75 ± 2.50
45.75 ± 3.59
-6.98 ± 5.02
47.25 ± 2.50
-10.63 ± 4.94
133.75 ± 5.50
128.00 ± 9.83
4.40 ± 3.48
120.25 ± 9.21
10.12 ± 5.08

P
0.898
0.065
˂ 0.001
0.036
˂ 0.001
0.745
0.021
0.01
0.009
0.009
0.044
0.024
0.410
0.010
0.649
0.221
0.272
0.752
0.304
0.842
0.207
0.113
0.965
0.165
0.938
0.684
0.299
0.469
0.293
0.620

Table 3: P values of the percentage change in FPG and HbA1C of AC and CC genotypes when compared to wild
type genotype AA.
Genotype

P

FPG % change after 3 months
FPG % change after 6 months
HbA1C % change after 3 months
HbA1C % change after 6 months
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AC
0.676
0.414
0.040
0.037

CC
˂ 0.001
˂ 0.001
0.011
0.011
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4. DISCUSSION
Among the classes of oral hypoglycemic agents available in Lebanon for the treatment of T2DM,
metformin remains one of the most prescribed drugs. The organic cation transporter 1 (OCT1) also known as
SLC22A1 is responsible for metformin uptake in hepatocyte. Single nucleotide polymorphisms in OCT1 have
been recognized as a possible mechanism explaining inter-individual variation in metformin response.
In this study we evaluated the distributive characteristics of SLC22A1 rs622342 polymorphisms and the
possible influence of these polymorphisms on metformin’s effect in Lebanese T2DM patients.
Several studies have been conducted in order to link OCT1 variants to the clinical efficacy of metformin,
however results remain controversial. Shu et al. ,2008 showed no effect of R61C and 420del in OCT 1 on a
number of outcomes, including
HbA1c reduction. Becker et al.,2009 analyzed 11 single nucleotide
polymorphisms in the SLC22A1 gene and change in the HbA1c level. Except for the rs622342 polymorphism,
no significant differences in metformin response were observed. Singh et al., 2016 showed that the allele and
genotypes of SLC22A1 rs622342 gene polymorphism were associated with the therapeutic efficacy of
metformin in South Indian patients with T2DM. Tkac et al.,2013 showed no significant association with
SLC22A1 rs622342 and SLC22A2 rs316019 gene polymorphisms and HbA1c reduction.
Our results showed a significant correlation between rs622342 polymorphisms and the reduction of both
fasting plasma glucose and glycosylated hemoglobin in patients who were on metformin monotherapy. No
significant correlation between rs622342 polymorphisms and the variation of lipid profile were shown. These
results suggest that Carriers of the allele ‘C’ are less responsive to metformin treatment than the wild type.
This effect could be related to metformin’s altered pharmacokinetics.
5. CONCLUSIONS
Metformin therapy is less effective in reducing glucose and HbA1c levels in diabetes mellitus Lebanese
patients carrying the C allele at SNP rs622342 of SLC22A1 than it is in wild-type AA patients. The study
suggests that genetic variation in OCT1 may be associated with variation in response to metformin. However,
these results need validation in a larger cohort study.
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